Ginkgo Bioworks Holdings Inc. shares
DNA,
were rising more than 5% in Monday’s premarket trading after the company said it was collaborating with Merck & Co. Inc.
MRK,
on improvements in biologic manufacturing. Ginkgo plans to use its abilities in cell engineering, ultra high-throughput multiplexed screening, protein characterization and process optimization to boost yields and drive improvements in production efficiency. The company is eligible to rake in an aggregate total of $490 million in upfront research fees, research milestone fees, option license payments and commercial milestone payments, according to its release.
